{"id":"W4281715825","doi":"10.1200/jco.2022.40.16_suppl.11523","title":"Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iterion Therapeutics","keywords":"Medicine; Internal medicine; Maximum tolerated dose; Adverse effect; Nuclear medicine; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001467852,0.001128496,0.001317374,0.0003361313,0.000349318,0.0005865082,0.0006072185,0.0007460834,0.002037753],"category_scores_gemma":[0.0006070152,0.0004063166,0.0008072755,0.0003443064,0.0004585063,0.000493951,0.0002336325,0.002277007,0.0005274138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001088776,"about_ca_system_score_gemma":0.001348251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00121589,"about_ca_topic_score_gemma":0.002988967,"domain_scores_codex":[0.999535,0.0002002717,0.00002956564,0.00007305907,0.00006766971,0.00009454537],"domain_scores_gemma":[0.9995033,0.00007461599,0.00009991895,0.00004733508,0.00004309929,0.0002317312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3049271,0.152735,0.02156145,0.001121546,0.002666582,0.0008085751,0.0007056022,0.01247578,0.2897513,0.0004613689,0.01120873,0.2015771],"study_design_scores_gemma":[0.1537786,0.7465064,0.05686443,0.00005410213,0.001243506,0.001115887,0.0001115761,0.003261913,0.02784655,0.0003043752,0.008861858,0.00005095986],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910676,0.001494466,0.0008850996,0.0002605076,0.0000464667,0.002377501,0.001795018,0.0001035568,0.001969827],"genre_scores_gemma":[0.9888704,0.001046541,0.002271708,0.0004270052,0.00004405238,0.001616551,0.003854296,0.00003944137,0.001829981],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002037753,"threshold_uncertainty_score":0.007899702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07077747817959736,"score_gpt":0.4341381408203555,"score_spread":0.3633606626407581,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}